KLOW Blend:
GHK-Cu, KPV, TB-500 & BPC-157
KLOW is a four-peptide research blend combining GHK-Cu, KPV, TB-500, and BPC-157. Formulated for researchers investigating skin repair, anti-inflammatory signaling, and regenerative mechanisms through complementary multi-peptide pathways.
What Is KLOW?
KLOW is a four-peptide research blend developed by Lumen Peppers, combining GHK-Cu (copper tripeptide), KPV (Lys-Pro-Val, the C-terminal tripeptide of α-MSH), TB-500 (Thymosin Beta-4 fragment), and BPC-157. Compared to GLOW, KLOW adds KPV — a potent MC1R-activating tripeptide with direct anti-inflammatory and barrier-repair activity — making it particularly suited for research focused on inflammation-driven skin and gut tissue models.
KLOW addresses four overlapping but distinct regenerative axes: copper-mediated ECM remodeling (GHK-Cu), melanocortin anti-inflammatory signaling (KPV), actin-cytoskeletal cell migration (TB-500), and angiogenic/growth factor support (BPC-157). Lumen Peppers provides KLOW as a research-grade lyophilized blend for in vitro and preclinical laboratory investigation only.
Key Research Findings
KLOW components have been studied across skin biology, gut inflammation, wound healing, and regenerative models.
KPV: MC1R Activation & NF-κB Suppression
KPV (Lys-Pro-Val) is the C-terminal sequence of α-MSH that retains full melanocortin receptor binding and anti-inflammatory activity in a stable tripeptide form. It activates MC1R, suppresses NF-κB nuclear translocation, and reduces TNF-α and IL-1β in keratinocyte and macrophage models with high potency at nanomolar concentrations.
GHK-Cu: Collagen, Elastin & Barrier Genes
GHK-Cu activates TGF-β1-driven collagen synthesis and upregulates critical skin barrier genes including FLG (filaggrin) and CLDN1 (claudin-1) in transcriptomic studies. The copper complex also activates lysyl oxidase for collagen cross-linking, contributing to structural ECM reinforcement.
TB-500: Cell Migration & Angiogenesis
TB-500's Ac-SDKP fragment modulates G-actin dynamics to enable keratinocyte migration across wound gaps. In vivo rodent studies show accelerated wound re-epithelialization with TB-500 administration. Thymosin Beta-4 also upregulates VEGF and MMP-2 at wound edges, coordinating angiogenic and remodeling phases.
BPC-157: Growth Factor Stabilization
BPC-157 stabilizes receptor-ligand interactions for EGF and VEGF in wound microenvironments. Its interaction with the FAK-paxillin focal adhesion pathway promotes fibroblast attachment and proliferation. BPC-157 also accelerates anastomosis formation in ischemic flap models.
Gut Inflammation Models
KPV demonstrates barrier-protective effects in DSS-induced colitis mouse models, reducing intestinal permeability and mucosal immune infiltration. BPC-157 shows complementary activity in gut fistula and anastomosis repair models. Combined, KLOW provides a multi-target tool for intestinal barrier research.
Complementary Pathway Coverage
KLOW targets four distinct repair cascades simultaneously: MC1R/NF-κB (KPV), TGF-β1/collagen (GHK-Cu), actin/migration (TB-500), and VEGF/EGF (BPC-157) — enabling researchers to study multi-pathway synergy in a single experimental system.
Proposed Mechanisms of Action
KPV binds MC1R (Gs-coupled GPCR) on keratinocytes, melanocytes, and immune cells, increasing intracellular cAMP. Elevated cAMP activates PKA, which phosphorylates IκB kinase — preventing NF-κB nuclear translocation. This suppresses transcription of TNF-α, IL-1β, IL-6, and COX-2 in inflamed tissue models.
GHK-Cu delivers Cu²⁺ to copper-dependent enzymes including lysyl oxidase (LOX), which cross-links collagen and elastin fibers. Simultaneously, GHK-Cu activates TGF-β1/Smad2/3 signaling, driving collagen I/III gene transcription — producing both structural ECM (via LOX) and new collagen substrate simultaneously.
Ac-SDKP sequesters G-actin monomers at the pointed end, reducing F-actin polymerization and enabling cytoskeletal reorganization required for lamellipodia-driven cell migration. TB-500 also upregulates VEGF mRNA in stromal cells, coordinating angiogenic sprouting with the migratory repair phase.
BPC-157 activates focal adhesion kinase (FAK) and paxillin in fibroblasts, promoting integrin-mediated attachment to ECM proteins. It also upregulates eNOS, increasing nitric oxide bioavailability at repair sites — contributing to vasodilatation, macrophage modulation, and growth factor receptor sensitization.
GHK-Cu and KPV converge on Nrf2 (cytoprotective) and NF-κB (inflammatory) regulation from complementary upstream nodes — GHK-Cu via antioxidant response element (ARE) activation, KPV via MC1R/cAMP/PKA. This dual-pathway anti-inflammatory convergence amplifies suppression of oxidative and inflammatory stress markers.
Active Research Applications
Skin Inflammation Models
Keratinocyte NF-κB, cytokine suppression, and barrier gene expression studies combining KPV MC1R activation with GHK-Cu collagen support.
Gut Barrier Research
Intestinal epithelial permeability, tight junction protein expression, and mucosal repair models in DSS-colitis and TNBS-induced inflammation.
ECM & Wound Biology
Collagen synthesis, elastin remodeling, fibroblast proliferation, and scratch assay migration studies across all four blend components.
Comparative Blend Studies
Head-to-head comparisons of KLOW vs. GLOW vs. individual peptides to isolate the contribution of KPV's MC1R axis to overall repair outcomes.
Hair & Follicle Biology
Anagen promotion, follicle cycling, and scalp inflammation models combining GHK-Cu follicle cycling, BPC-157 vascularization, and KPV anti-inflammatory activity.
Cosmeceutical R&D
In vitro testing platform for peptide cosmetic formulations studying multi-axis anti-aging and repair endpoints simultaneously.
Protocol Notes for Researchers
Related Research Compounds
KLOW Blend — Research Grade ≥99%
Research-grade purity ≥99% · Third-party HPLC verified · Ships from the U.S.
All products sold by Lumen Peppers are intended exclusively for in vitro laboratory research and investigative purposes. These compounds are not approved by the FDA for human or veterinary use. They are not drugs, supplements, or medications. Lumen Peppers makes no therapeutic claims. Researchers are solely responsible for ensuring compliance with all applicable laws and regulations in their jurisdiction.